HEALEY ALS Platform Trial

Accelerating the Path to Effective Treatments

Healey & AMG Center faculty, in partnership with the Northeast ALS (NEALS) Consortium, designed this first-of-its-kind Platform Trial for ALS leveraging input from ALS scientists and clinicians, industry partners, regulators and people living with ALS across the globe. This is a multicenter, double-blind, placebo-controlled, perpetual, adaptive platform trial testing multiple investigational products in parallel until we find safe and effective treatments for people living with ALS.

The HEALEY ALS Platform Trial is a collaborative effort, and enrollment in the trial is available at several sites across the US to bring the trial close to people who want to participate. If you have site-specific questions, please click here to contact the site where you would like to participate. For general inquiries, please contact HealeyAMGCenterforALS@mgh.harvard.edu.

This groundbreaking approach cuts the time to find an effective treatment in half, decreases costs by a third or more, and is supported by our patients, the FDA, ALS clinicians and scientists and our pharma colleagues.

  Merit Cudkowicz, MD, MSc
Director, Sean M. Healey & AMG Center for ALS

New investigational products are added to the HEALEY ALS Platform Trial, supported by pharma, foundation partners, philanthropy, federal and other fundraising initiatives. Academic and industry colleagues are encouraged to engage with the Healey Center ALS Trial Design Team at any time to work together on ALS therapy development. Nominations of products for inclusion in the platform trial will continue on an ongoing, rolling basis.